Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess efficacy and safety of Cenobamate in adult patients with uncontrolled focal seizures in a real-world setting

Next Previous
Trial Profile

To assess efficacy and safety of Cenobamate in adult patients with uncontrolled focal seizures in a real-world setting

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Seizures
  • Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

  • 28 Jun 2022 Results (n=20) assessing efficacy and safety of cenobamate in a real-life setting, presented at the 8th Congress of the European Academy of Neurology.
  • 20 Oct 2021 New trial record
  • 01 Sep 2021 Results presented at the 34th International Epilepsy Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top